Author Archive for Pharmboy

Epizyme – A Waiting Game

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Epizyme was founded in 2007, and trying to create drugs to treat patient's cancer by focusing on genetically-linked differences between normal and cancer cells. Cancer areas of focus include leukemia, Non-Hodgkin's lymphoma and breast cancer.  One of the Epizme cofounders, H. Robert Horvitz, won the Nobel Prize in Medicine in 2002 for "discoveries concerning genetic regulation of organ development and programmed cell death."

Before discussing the drug targets of Epizyme, understanding epigenetics is crucial to comprehend the company's goals.  

Genetic components are the DNA sequences that are 'inherited.'  Some of these genes are stronger than others in their expression (e.g., eye color).  Yet, some genes turn on or off due to external factors (environmental), and it is understanding the regulation of these genes that brings the term 'epigenetics.'  In other words, epigenetics does not have to be a nucleotide change in the DNA itself, but rather a functional regulation of the gene's expression.

Genes expression are controlled by many mechanisms, but Epizyme is focused on DNA methylation. DNA methylation is important for the regulation of gene expression, and functions normally to silence genes in genomic imprinting, X-chromosome inactivation, repressing repetative elements, aging, and cancer.  Two specific enzymes, DOT1L & EZH2 are the focus of the Company, and are DNA methylation enzymes (ie, Epizyme!!).  By inhibiting these two enzymes, cancer repressor genes will be turned on, and in conjunction with other chemotherapy agents, cancers may be repressed.

Early on, the Company raised $54M, and then GSK and Eisai signed up and pumped in $26M,  In May 2013, the Company went public for about $15 (5.9M shares at the time were sold), and shot out of the gate with a 50% premium the first day of trading to ~ $23.  The company was a darling.  While the company had two drugs in clinic, the compounds were very early on in clinical trials, but things were looking promising.   In Phase 1 data for their EZH2 inhibitor, tazemetostat, in genetically defined solid tumors of NHL, the overall response rate (ORR) was ~ 56% ((May 2015) which is very good!).  The phase 2 data…
continue reading





This Is Why Biotech Stocks May Explode Again

Reminder: Pharmboy and Ilene are available to chat with Members.

Here's an interesting article from Investor's Business Daily arguing that biotech stocks are beginning to recover from their recent declines, notwithstanding current weakness.

This Is Why Biotech Stocks May Explode Again

By 

Excerpt:

After a three-year bull run that more than quadrupled its value by its peak last July, IBD’s Medical-Biomed/Biotech Industry Group plunged 50% by early February, hurt by backlashes against high drug prices and mergers that seek to lower corporate taxes.

[...]

The group was up by even more before taking some hits over the past two weeks on negative earnings news from several industry players. But fund managers tell IBD the rebound is here. 

Why? For one, they say, the spate of bad news has already been factored into stock prices. But more than that, they see a climate favoring rejuvenated M&A, hot drugs in the new-product pipeline and pricing power for innovate products.

Bottom line: The positive factors that drove the runup never went away, they say. They just got drowned out by the noise.

“A very key point is that this group is a very high-beta group — particularly the small- to midcap stocks. Since they don’t have sales, they don’t have earnings,” said Tom Vandeventer, portfolio manager at Tocqueville Asset Management.

“The history of this group is that elevated macro uncertainty definitely hits (it),” Vandeventer said. “My own opinion is this group trades more on sentiment than on fundamentals during those time periods.”

Full article here >





Endo International plc – Ordinary Shares (ENDP) Collapses Taking Hedge Fund Returns With It

Reminder: Pharmboy and Ilene are available to chat with Members.

By Jacob Wolinsky. Originally published at ValueWalk.

Endo International plc – Ordinary Shares (ENDP) shares are crashing and when I say crashing I do not mean one percent or two percent or five percent or ten percent but at the time of this writing 38 percent. The biotech company is having a Valeant style crash and like Valeant ENDP is a big hedge fund hotel stock and it is likely killing returns for many, unless there is a big rebound soon.

Endo International plc - Ordinary Shares

Endo International plc – Ordinary Shares

As ZeroHedge notes (parenthesis ours):

The pain, however, is especially acute for a lot of hedge funds, because as Goldman reminds us after the spectacular blow ups of Valeant and Allergan, and recently, the plunge in uber hedge fund hotel AAPL, Endo itself is one of the stocks that has the highest hedge fund concentration in the S&P.

Endo International plc - Ordinary Shares

Endo International plc – Ordinary Shares

Who are these hedge funds? Most of the usual suspects including Visium (which is also having other issues), Viking Global (more pain), Paulson (shocker), Brahman, MSD and of course countless bank prop desks as listed below.

Endo International plc - Ordinary Shares

So if we report next week that the "smart money outflows" have continued for a record 15th week, we will know who the weekly scapegoat is for the latest redemption deluge as panicking hedge funds are forced to liquidate other assets to cover for their massive P&L blow ups in ENDP this morning.

Endo International plc – Ordinary Shares

The sell…
continue reading





Cantor Says Relypsa’s Veltassa Metrics Look Favorable

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Courtesy of Benzinga.

Positive Data Points For Veltassa Launch

Veltassa metrics look favorable so far, including a low payer rejection rate of ~20 percent, conversion from starter pack to prescriptions between 50 and 60 percent and in-line gross-to-net discount of approximately 25 percent.

Veltassa sales, albeit modest, were ahead of expectations. Veltassa sales came in at $0.6 million, compared to the 1Q16 estimate of $0.25 million. Relypsa had previously reported 1,155 outpatient prescriptions and 374 hospital/institution units sold in the quarter.

“Excluding gross-to-net discounts, sales would have been $0.8 million. Our expectation for 1H:16 has been modest, as we expect 2H:16, and in particular 4Q:16 to create visibility on Veltassa's sales potential,” analyst Mara Goldstein wrote.

Relypsa’s shares have come under pressure because investors may be viewing the debt financing as a major obstacle to a potential takeout of the company, Goldstein commented, while adding, “We continue to like the shares because of our view of the potential of Veltassa and hyperkalemia market overall.” She expects 3Q16 to be an inflection point for Veltassa, and could result in a realignment of valuation.

Latest Ratings for RLYP

Date Firm Action From To
May 2016 BTIG Research Maintains   Buy
May 2016 Cantor Fitzgerald Maintains   Buy
May 2016 Mizuho Securities Downgrades Neutral Underperform

View More Analyst Ratings for RLYP

View the Latest Analyst Ratings

Related
BTIG Cuts Veltassa Estimates, Relypsa's Price Target To $35
Mizuho Downgrades Relypsa, Says Near-Term Takeout 'Unlikely'
Relypsa's (RLYP) CEO John Orwin on Q1 2016 Results – Earnings Call Transcript (Seeking Alpha)

Posted-In: Cantor Fitzgerald Mara GoldsteinAnalyst Color Long Ideas Price Target Reiteration Analyst Ratings Trading Ideas





PRGO, VRX and the Papa of “Strong Shareholder Orientation”

Reminder: Pharmboy and Ilene are available to chat with Members.

By Ilene 

Remember this? It was Monday. PRGO is down from around $130 to under $100 since I started following it LAST WEEK. That's down almost 25% in a week, and almost 50% in the last year. I commented: 

"Perrigo CEO Joseph Papa leaves Perrigo (PRGO) to lead Valeant (VRX) while PRGO issues a warning about missing earnings expectations. Not surprisingly, PRGO stock plummeted today. 

Robert Ingram, Chairman of the [Valeant] Board, stated, "The Board has conducted a thorough search process and believes that Joe is the ideal leader for Valeant at this time. He has a strong shareholder orientation, a background in science, and an unmatched track record of accomplishments, highlighted by his ability to lead companies through times of transition and drive excellence across commercial, manufacturing and R&D platforms. In addition, fostering an ethical culture and creating opportunities for professional development have always been high priorities for Joe, and we look forward to Joe's arrival at Valeant" (Valeant names Papa CEO after he resigns from Perrigo).

"Reuters reports that Mr. Shareholder Orientation became 'well-known on Wall Street last year when Dublin-based Perrigo rebuffed a $26 billion takeover by Mylan NV, the largest-ever hostile bid decided by a shareholder vote.' Perrigo's market cap has now dropped to around $14.2 billion [now $13.9 billion] — down over 18% today alone -- making Papa look foolish for rejecting that buyout offer."

So after successfully (but not intelligently) fighting a $26 billion hostile takeover bid from Mylan, Perrigo reports disappointing quarterly results and it "slashes its outlook" (Perrigo shares tumble as CEO leaves for Valeant, guidance cut again). The stock has been in free fall and Papa is described as having a "strong shareholder orientation" and an "ethical culture."

While many were congratulating VRX for recruiting Papa to be its CEO, Jim Cramer wrote,

Perrigo's (PRGO) heartbreaking. How could Joe Papa, the man who was so intertwined with Perrigo for so long, the man who came on Mad Money and argued there was so much more value to the company than the price Mylan put on it — some 80 points higher than where it went out —


continue reading





Sarepta Plunges 50% After FDA Rejects Key Drug

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Sarepta Plunges 50% After FDA Rejects Key Drug

Courtesy of ZeroHedge. View original post here.

2016 has been a tempestuous year for Serepta shareholders. From over $40 to just $10 and then the miracle ramp from february back to $25 before the writing on the wall ahead of last night's FDA decision and now – following yesterday's monstrous short-squeeze (36% surge), a 50% collapse to $8 – a 4 year low for yet another Biotech darling of old. This morning's collapse comes after the FDA voted that SRPT's muscular dystrophy drug was not effective

As Bloomberg reports,

An FDA advisory panel voted 7-3 with 3 abstentions that Sarepta’s single historically controlled study doesn’t provide substantial evidence that eteplirsen is effective for treatment of Duchenne muscular dystrophy (DMD).

Some panel members raised questions about study design, said more data are needed.

Not a great morning for Stevie Cohen who just upped his stake (seems he did not get the nod this time)…

Any questions, refer to Christopher Marai or Chad Messer (PhD!)…





Perrigo Company plc (PRGO) Tanks As CEO Leaves For Valeant (VRX)

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Perrigo Company plc (PRGO) Tanks As CEO Leaves For Valeant (VRX)

By Jacob Wolinsky. Originally published at ValueWalk.

Perrigo Company plc (PRGO) Tanks As CEO Leaves For Valeant (VRX) – it was a decent day to be a VRX shareholder and a bad day to be a PRGO and if your initials are JP it was a really bad day … being shareholders of both companies. As JPMorgan notes: This morning, Perrigo announced the appointment of John Hendrickson (former President) as CEO, replacing Joe Papa who is set to become the CEO of Valeant. The company also provided disappointing preliminary 1Q results and significantly lowered full year 2016 EPS to $8.20-$8.60 (vs. prior range of $9.50-$9.80) due to Rx pricing pressure, continued underperformance of the Branded Consumer business, and lower expectations for new product launches.

Perrigo Company plc CEO leaves for VRX analysts react

RBC

There will be several who focus on recent challenges and the need for someone from the outside to come in and help turn PRGO around. But on the other hand, John Hendrickson has been with PRGO since 1989 and led key operations including VP of Manufacturing to EVP and General Manager of Consumer Health to its current President among others and this should minimize any disruption at a time where operational focus is critical. He also understands the Consumer Health business well which is the highest value part of PRGO’s business. PRGO also mentioned that Omega head Marc Coucke’s Board nomination has been withdrawn by the nominating and governance committee.

Morgan Stanley

New CEO has strong experience at Perrigo Company plc. Mr. John Hendrickson has served as President of PRGO since October 2015, following his prior roles as EVP, Global Operations & Supply Chain (2006 -2015) and the head of US Consumer Healthcare (2003-2006). A 27-year veteran at Perrigo, he joined the company in 1989. With the resignation of current Chairman and CEO Joseph Papa, the role of Chairman will now be separated from the CEO role. The board has elected Independent Director Laurie Brlas as PRGO new Chairman.

Goldman Sachs

PRGO announced the resignation of former CEO Joe Papa and promotion of former President John Hendrickson as new CEO. Mr. Hendrickson has been at PRGO since 1989 in various roles including leading the US Consumer…
continue reading





The Michael Pearson Era Is Officially Over: Valeant Appoints Joseph Papa As Chairman And CEO

Reminder: Ilene and Pharmboy are available to chat with Members, comments are found below each post.

Perrigo CEO Joseph Papa leaves Perrigo (PRGO) to lead Valeant (VRX) while PRGO issues a warning about missing earnings expectations. Not surprisingly, PRGO stock plummeted today. 

Robert Ingram, Chairman of the [Valeant] Board, stated, "The Board has conducted a thorough search process and believes that Joe is the ideal leader for Valeant at this time.  He has a strong shareholder orientation, a background in science, and an unmatched track record of accomplishments, highlighted by his ability to lead companies through times of transition and drive excellence across commercial, manufacturing and R&D platforms.  In addition, fostering an ethical culture and creating opportunities for professional development have always been high priorities for Joe, and we look forward to Joe's arrival at Valeant" (Valeant names Papa CEO after he resigns from Perrigo).

Reuters reports that Mr. Shareholder Orientation became "well-known on Wall Street last year when Dublin-based Perrigo rebuffed a $26 billion takeover by Mylan NV, the largest-ever hostile bid decided by a shareholder vote." Perrigo's market cap has now dropped to around $14.2 billion — down over 18% today alone -- making Papa look foolish for rejecting that buyout offer.

Papa’s departure comes just months after he successfully beat back a $26 billion hostile takeover bid from Mylan [MYL] spearheading a campaign that ultimately persuaded shareholders to reject Mylan’s bid.

Since then, though, Perrigo has reported disappointing quarterly results and slashed its outlook. (Perrigo shares tumble as CEO leaves for Valeant, guidance cut again)

Papa's recent record at PRGO reveals not only bad judgment but also, more disturbing, a lack of ordinary CEO loyalty. As Jim Cramer writes,

Perrigo's (PRGO) heartbreaking. How could Joe Papa, the man who was so intertwined with Perrigo for so long, the man who came on Mad Money and argued there was so much more value to the company than the price Mylan put on it — some 80 points higher than where it went out — just leave for Valeant (VRX)? How could he leave with a huge shortfall and some weird impairment charge about an acquisition that Papa crowed about, Omega, as a way to get international exposure?

There wasn't a single


continue reading





Perrigo: BTFD – Times Two?

Reminder: Ilene is available to chat with Members, comments are found below each post.

Update: PRGO may be losing its CEO to Valeant: Valeant’s Latest Acquisition Target: Perrigo’s CEO?. This news is knocking the price down into the low $120s. Paul says he is buying more shares and selling 2018 puts with a strike price of $150. See the screenshot below. Paul sold those three 2018 $150 puts.

Paul writes, "A forced change at the CEO level and PRGO’s depressed share price might induce management to reconsider its refusal to sell at above $200 when Mylan came calling last year. Shareholders are unhappy meaning something is likely being planned to get the stock moving again."

Updated chart:

As originally posted April 20, 2016. 

On June 10, 2015, Paul Price gave us a trade idea on BAX. Baxter Int. (BAX) was trading at around $66/share and scheduled to split off Baxalta (BXLT), its BioScience division, in the ratio of one share of BXLT for each share of BAX. BXLT is now at $40.65 and BAX is at $43.40. 

Baxter Int. (BAX) is splitting off its BioSciences division into a new company called Baxalta. Shares of Baxalta will be given as a tax-free dividend, in the ratio of one to one, to BAX holders on record on June 17, 2015. 

If you bought BAX, and held both companies after the split, till today, you'd have about a 27% gain. (Both Phil and Paul also suggested selling puts, see the article for more details.)

Now, for about a month, Paul's been suggesting buying and/or selling puts on Perrigo (PRGO, $129) at TheStreet.com's Real Money Pro (paywall) and Guru Focus. PRGO has been languishing around $128 – 130 and he thinks this area makes a good entry point for a longer term trade. Here are several excerpts from Paul's recent article at Real Money Pro with some updated charts. 

Healthcare products provider Perrigo (PRGO) has a fabulous long-term record. The stock dropped sharply on Feb. 18, 2016, as the firm took a charge in its latest quarter for costs associated with fighting off a hostile takeover attempt from Mylan (MYL). 


continue reading





Baxter’s Spinoff

Reminder: Pharmboy and Ilene are available to chat with Members, comments are found below each post.

Baxter Int. (BAX) is splitting off its BioSciences division into a new company called Baxalta. Shares of Baxalta will be given as a tax-free dividend, in the ratio of one to one, to BAX holders on record on June 17, 2015. That means, if you want to receive the Baxalta dividend, you need to buy the stock this week (on or before June 12).

The Baxalta Spinoff

By Ilene with Trevor of Lowenthal Capital Partners and Paul Price

In its recent filing with the SEC, Baxter provides:

“This information statement is being furnished in connection with the distribution by Baxter International Inc. (Baxter) to its shareholders of approximately 80.5% of the outstanding shares of common stock of Baxalta Incorporated (Baxalta), a wholly owned subsidiary of Baxter that will hold directly or indirectly the assets and liabilities associated with Baxter’s biopharmaceuticals business. To implement the distribution, Baxter will distribute approximately 80.5% of the shares of Baxalta common stock on a pro rata basis to the Baxter shareholders in a manner that is intended to be tax-free for U.S. federal income tax purposes.”

“As a result of the separation, each Baxter shareholder will receive one share of Baxalta common stock for every Baxter share of common stock held on June 17, 2015, the record date for the distribution.”

Trevor Lowenthal at Lowenthal Capital Partners, Paul Price and I have been reviewing Baxter and its upcoming spinoff of Baxalta. We believe that the spinoff will unleash value from the Baxalta bioscience division of the company and that the sum of the BAX parts will prove to be greater than the whole.  Baxalta should benefit from growing market penetration for Advate, the number one selling therapy in its hemophilia franchise, along with the approval of important new products. This should enhance long-term value for current BAX shareholders as Baxalta's new products hit the market and as the independent company gets priced more in line with its growth prospects. 

In April, Trevor Lowenthal shared his thoughts on BAX in Going Long On Baxter For An Optimistic 2016. To summarize:

  • Baxter has experienced several lackluster quarters, but the company's revenues are growing and its positive outlook


continue reading





 
 
 

Zero Hedge

Final Q2 GDP Comes At 1.4%: US Set To Grow At Slowest Pace Since Financial Crisis

Courtesy of ZeroHedge. View original post here.

While the second quarter is now ancient history and the debate is how much the predicted rebound in Q3 GDP will fade into Q4 which is set to begin in just three days, moments ago the BEA released its final revision for Q2 GDP, according to which real GDP increased 1.4% in the second quarter of 2016, 0.3 % higher than the “second” estimate released in August, and fractionally higher than the 1.3% expected. In the first quarter, real GDP rose 0.8 percent.

...



more from Tyler

ValueWalk

Here's Why The Pundits Are Wrong About Warren Buffett

By VW Staff. Originally published at ValueWalk.

Here’s Why The Pundits Are Wrong About Warren Buffett via Roger Lowenstein, Fortune

]]> Get The Full Warren Buffett Series in PDF

Get the entire 10-part series on Warren Buffett in PDF. Save it to your desktop, read it on your tablet, or email to your colleagues.

We respect your email privacy

It takes a lot of cherry-picking to make him look bad.

Norman Pearlstine, the vice chairman and longtime editorial soul of Time Inc., which publishes Fortune, once said that every feature story fit into one of three archetypes: &...



more from ValueWalk

Phil's Favorites

India Raids Pakistan, Claims "Significant Casualties" Inflicted: Don't Worry It's Just a "Surgical Strike"

Courtesy of Mish.

Border skirmishes between India and Pakistan have been going on for years. But with social mood darkening everywhere, and with India making the claim ‘Significant casualties’ inflicted on ‘launch pads’ for militant attacks, one can’t help but wonder when this erupts in a major way.

The Financial Times reports India launches ‘surgical strikes’ on Pakistan terror targets.

India said it had carried out “surgical strikes” overnight across its disputed border with Pakistan to target groups of militants that were allegedly planning to carry out terror attacks on Indian territory.

...

more from Ilene

Market News

News You Can Use From Phil's Stock World

 

Financial Markets and Economy

Just as it's been announced, US oil producers may readying to thwart OPEC's plan (Business Insider Australia)

While the specifics over how it will be achieved are as yet unknown, and there are already signs that some members are uncomfortable with the decision, it appears that OPEC will reduce oil output for the first time in eight years when the grou...



more from Paul

Mapping The Market

The Industry That Was Crushed By The Obama Administration

By Jean-Luc

Good riddance – cleaned up a lot of frauds there:

The Industry That Was Crushed By The Obama Administration

In early 2009, the seven largest publicly traded college operators were worth a combined $51 billion. Today, they’ve been all but wiped out.

When Barack Obama took office, America’s seven largest publicly traded college operators were worth a combined $51 billion, with more than 815,000 students enrolled at campuses spread across the country. The schools were flooded with with people seeking shelter from the recession, returning to school to pick up new skills.

Almost eight years later, the industry has been decimated. The seven largest listed operators are worth just over $6 billion, and the most valuable co...



more from M.T.M.

Kimble Charting Solutions

Japanese YEN testing triple breakout level

Courtesy of Chris Kimble.

Below looks at the Japanese Yen over the past 20-years.

For the majority of the time, the YEN has remained inside of rising channel (A). Now a big test is in play, after breaking support.

CLICK ON CHART TO ENLARGE

The Yen remained inside rising channel (A) from the mid 1990’s until 2014, where it broke below rising support. The rally that has taken place since the lows ...



more from Kimble C.S.

Chart School

RTT browsing latest..

Courtesy of Read the Ticker.

Please review a collection of WWW browsing results.



Date Found: Saturday, 26 March 2016, 02:36:15 PM

Click for popup. Clear your browser cache if image is not showing.
Comment: ZH: Its a BULLARD market, the FED jaw boning is keeping the market up!



Date Found: Sunday, 27 March 2016, 02:31:30 PM

Click for popup. Clear your browser cache if image is not showing.
Comment: RTT: World trade near 2008/09 lows. SP500 near all time highs. PLACE YOUR BETS! Roll up! Roll up!



Date Found: Tuesday, 29 March 2016, 02:42:11 PM

Click for popup. Clear your browser cach...



more from Chart School

OpTrader

Swing trading portfolio - week of September 26th, 2016

Reminder: OpTrader is available to chat with Members, comments are found below each post.

 

This post is for all our live virtual trade ideas and daily comments. Please click on "comments" below to follow our live discussion. All of our current  trades are listed in the spreadsheet below, with entry price (1/2 in and All in), and exit prices (1/3 out, 2/3 out, and All out).

We also indicate our stop, which is most of the time the "5 day moving average". All trades, unless indicated, are front-month ATM options. 

Please feel free to participate in the discussion and ask any questions you might have about this virtual portfolio, by clicking on the "comments" link right below.

To learn more about the swing trading virtual portfolio (strategy, performance, FAQ, etc.), please click here ...



more from OpTrader

Members' Corner

Market Liquidity and Macroeconomic Bullshit

 

Market Liquidity and Macroeconomic Bullshit

Courtesy of The Nattering Naybob

STJL - "Apparently macroeconomics is all bullshit – ROFL! Paging Naybob now… Famous Economist Paul Romer Says Macroeconomics Is All Bullshit."

The Nattering One muses... Macroeconomics as practiced by academics and those in charge is pure voodoo. Better to chant over goat blood, bird feathers and scattered entrails...

As for reality, overnight CNH HIBOR (...



more from Our Members

Digital Currencies

Gold, Silver and Blockchain - Fintech Solutions To Negative Rates, Bail-ins, Currency Debasement and Cashless

Courtesy of ZeroHedge. View original post here.

By Jan Skoyles

I was so pleased yesterday by the announcement that I have joined the Research team at GoldCore as it meant that I could finally start talking about it and was back in a role that lets me indulge in my passion by researching and geeking out on all things gold, silver and money.

...



more from Bitcoin

Biotech

Epizyme - A Waiting Game

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Epizyme was founded in 2007, and trying to create drugs to treat patient's cancer by focusing on genetically-linked differences between normal and cancer cells. Cancer areas of focus include leukemia, Non-Hodgkin's lymphoma and breast cancer.  One of the Epizme cofounders, H. Robert Horvitz, won the Nobel Prize in Medicine in 2002 for "discoveries concerning genetic regulation of organ development and programmed cell death."

Before discussing the drug targets of Epizyme, understanding epigenetics is crucial to comprehend the company's goals.  

Genetic components are the DNA sequences that are 'inherited.'  Some of these genes are stronger than others in their expression (e.g., eye color).  Yet, some genes turn on or off due to external factors (environmental), and it is und...



more from Biotech

All About Trends

Mid-Day Update

Reminder: Harlan is available to chat with Members, comments are found below each post.

Click here for the full report.




To learn more, sign up for David's free newsletter and receive the free report from All About Trends - "How To Outperform 90% Of Wall Street With Just $500 A Week." Tell David PSW sent you. - Ilene...

more from David

Promotions

PSW is more than just stock talk!

 

We know you love coming here for our Stocks & Options education, strategy and trade ideas, and for Phil's daily commentary which you can't live without, but there's more!

PhilStockWorld.com features the most important and most interesting news items from around the web, all day, every day!

News: If you missed it, you can probably find it in our Market News section. We sift through piles of news so you don't have to.   

If you are looking for non-mainstream, provocatively-narrated news and opinion pieces which promise to make you think -- we feature Zero Hedge, ...



more from Promotions



FeedTheBull - Top Stock market and Finance Sites



About Phil:

Philip R. Davis is a founder Phil's Stock World, a stock and options trading site that teaches the art of options trading to newcomers and devises advanced strategies for expert traders...

Learn more About Phil >>


As Seen On:




About Ilene:

Ilene is editor and affiliate program coordinator for PSW. She manages the site market shadows, archives, more. Contact Ilene to learn about our affiliate and content sharing programs.

Market Shadows >>